Medicare Expands Coverage to Include GLP-1 Drugs for Weight Loss

By Simone Carter

Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) will implement a new initiative allowing Medicare beneficiaries to access GLP-1 medications specifically for weight loss. This temporary program, known as the Medicare GLP-1 Bridge, will run through December 31, 2027.

The program enables eligible Medicare Part D beneficiaries to obtain GLP-1 drugs like Foundayo®, Wegovy®, and Zepbound® (KwikPen® formulation only) for weight loss and maintenance. Participants will incur a $50 monthly copay, which is separate from the standard Part D benefit structure. The copay does not count toward the Part D deductible or the true out-of-pocket (TrOOP) threshold, and low-income subsidies do not apply.

Eligibility for the program requires beneficiaries to be enrolled in a standalone Prescription Drug Plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD). The drugs must be used solely for weight loss, not for other conditions such as diabetes or heart disease, which remain covered under standard Part D.

Beneficiaries must meet specific clinical criteria, including being at least 18 years old, having a body mass index (BMI) of 30 or higher, and possessing a qualifying comorbidity such as uncontrolled hypertension or chronic kidney disease stage 3a or higher.

Pharmacies will process claims through a designated central processor, with a dispensing fee of $3 per claim, or $5 in long-term care settings.